Literature DB >> 20230992

Photodynamic diagnosis (PDD) for upper urinary tract transitional cell carcinoma (UT-TCC): evolution of a new technique.

B K Somani1, H Moseley, M S Eljamel, G Nabi, S G Kata.   

Abstract

INTRODUCTION: Transitional cell carcinoma of renal pelvis and ureter account was traditionally treated with nephroureterectomy. With the advent of rigid and flexible ureteroscopes endoscopic access to the ureter and renal pelvis for diagnosis and treatment has become a reality. We did fluorescence ureteroscopy using oral 5-ALA to diagnose upper tract urothelial tumours for four patients. Here we describe this technique and assess its feasibility to diagnose ureteric and renal pelvicalyceal tumours.
MATERIALS AND METHODS: A prospective pilot study was performed to assess the feasibility of PDD using oral 5-amino levulinic acid (ALA) for upper urinary tract tumours.
RESULTS: Four patients underwent PDD guided flexible ureteroscopy of the upper urinary tract. Obvious exophytic tumour seen on white light was also seen as red fluorescence on blue light. All areas with red fluorescence were biopsied (including additional areas not seen on white light) and were confirmed to be transitional cell carcinoma.
CONCLUSION: Photodynamic diagnosis using oral 5-ALA and subsequent treatment of upper tract urothelial tumours is safe and feasible with additional advantages of detecting lesions not visualised on conventional white light endoscopy. 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20230992     DOI: 10.1016/j.pdpdt.2009.12.005

Source DB:  PubMed          Journal:  Photodiagnosis Photodyn Ther        ISSN: 1572-1000            Impact factor:   3.631


  16 in total

Review 1.  Which flexible ureteroscope is the best for upper tract urothelial carcinoma treatment?

Authors:  Etienne Xavier Keller; Steeve Doizi; Luca Villa; Olivier Traxer
Journal:  World J Urol       Date:  2019-02-15       Impact factor: 4.226

2.  [Elective organ and function preservation in ureter and renal pelvis tumors].

Authors:  S Rausch; G Gakis; J Bedke; A Stenzl
Journal:  Urologe A       Date:  2014-09       Impact factor: 0.639

Review 3.  Correlation of Operative Time with Outcomes of Ureteroscopy and Stone Treatment: a Systematic Review of Literature.

Authors:  Jenni Lane; Lily Whitehurst; B M Zeeshan Hameed; Theodoros Tokas; Bhaskar K Somani
Journal:  Curr Urol Rep       Date:  2020-03-24       Impact factor: 3.092

Review 4.  Nanomedicine associated with photodynamic therapy for glioblastoma treatment.

Authors:  Leonardo B de Paula; Fernando L Primo; Antonio C Tedesco
Journal:  Biophys Rev       Date:  2017-08-19

Review 5.  Risk-adapted strategy for the kidney-sparing management of upper tract tumours.

Authors:  Thomas Seisen; Pierre Colin; Morgan Rouprêt
Journal:  Nat Rev Urol       Date:  2015-02-24       Impact factor: 14.432

Review 6.  Role of Narrow Band Imaging in Management of Urothelial Carcinoma.

Authors:  Emanuela Altobelli; Dimitar V Zlatev; Joseph C Liao
Journal:  Curr Urol Rep       Date:  2015-08       Impact factor: 3.092

7.  A Pilot Study of In Vivo Confocal Laser Endomicroscopy of Upper Tract Urothelial Carcinoma.

Authors:  Daniel Bui; Kathleen E Mach; Dimitar V Zlatev; Robert V Rouse; John T Leppert; Joseph C Liao
Journal:  J Endourol       Date:  2015-10-06       Impact factor: 2.942

Review 8.  Predictors of Urinary Infections and Urosepsis After Ureteroscopy for Stone Disease: a Systematic Review from EAU Section of Urolithiasis (EULIS).

Authors:  Shreya Chugh; Amelia Pietropaolo; Emanuele Montanari; Kemal Sarica; Bhaskar K Somani
Journal:  Curr Urol Rep       Date:  2020-03-24       Impact factor: 3.092

9.  Surgical management of upper tract urothelial carcinoma.

Authors:  Vincent G Bird; Prashanth Kanagarajah
Journal:  Indian J Urol       Date:  2011-01

Review 10.  Nephron-sparing management of upper tract urothelial carcinoma.

Authors:  Jason M Farrow; Sean Q Kern; Gustavo M Gryzinski; Chandru P Sundaram
Journal:  Investig Clin Urol       Date:  2021-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.